Medtech

ONE 2023 Full Year Results Out - Plus Some Surprises…

Next Investors Feb 28, 2024

The market looks like it is rewarding the progress ONE made in 2023 laying the groundwork for a jump in growth during 2024.

Tell Me Why: The 10 Reasons We Invested in ONE

Next Investors Mar 19, 2021

Last Friday we announced our 2021 Tech Pick of the Year, Oneview Healthcare plc (ASX: ONE) - a healthcare technology company that enables ‘virtual care’ at the bedside for hospital patients. We promised that we would provide further analysis on why we have made such a large, long term investment and called ONE our 2021 Tech Pick of the Year…

Oneview’s MedTech combats COVID-19 and keeps everyone safe

Finfeed Archived Jul 31, 2020

A deep re-imagining of how healthcare and patient care is delivered. This is being facilitated by Oneview Healthcare (ASX: ONE), an ASX-listed health-tech provider, which this year launched a cloud-based solution to help healthcare systems manage hospitalised patients during and after COVID-19.

Respiri Limited signs joint development agreement with Phenix Health, surges 50%

Finfeed Archived Apr 14, 2020

Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management, signs a joint development venture agreement with Phenix Health Pty Ltd

Non-elective treatment profile provides Avita Medical with income stability

Finfeed Archived Apr 08, 2020

AVITA Medical Limited (ASX: AVH) is a med-tech stock worth targeting outside the blue chips such as ResMed, CSL and Ramsay Health Care.

Investors flock to Lifespot as a telehealth play

Finfeed Archived Mar 25, 2020

Lifespot Health Limited (ASX: LSH) Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices.

OncoSil granted FDA Breakthrough Device Designation

Finfeed Archived Mar 18, 2020

OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.

OncoSil on verge of CE Mark approval

Finfeed Archived Feb 27, 2020

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

Next Investors Archived Jan 30, 2020

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

HeraBEAT users could be in line for full refunds on the cost of the product

Finfeed Archived Dec 04, 2019

Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system.

HeraMED CEO David Groberman talks about the company’s progress

Finfeed Archived Dec 02, 2019

Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength, excelling in the area of product development and distribution, but also forging alliances with other global, high profile medical institutions.

BPH ready to cash in on high profile energy investments

Finfeed Archived Nov 26, 2019

Advent Energy, in which BPH Energy (ASX:BPH) has a 25% interest, had previously interpreted significant seismically indicating gas features indicating hydrocarbon accumulation following a review in 2004.

HeraMed to Spring-Board German Pre Natal Market Entry by Partnering with Telehealth Provider Kinderheldin

Next Investors Archived Nov 21, 2019

HeraMED (ASX:HMD) has signed an agreement with Kinderheldin to add online midwifery service to be offered as HeraBEAT PLUS in Germany.

Regeneus soars 60% as Japanese fund supports capital raising

Finfeed Archived Nov 19, 2019

Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.

Interview: Mike Harsh on the evolution of Imaging and Imagion's role

Finfeed Archived Nov 18, 2019

With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.

HeraMED receives FDA clearance for HeraBEAT

Finfeed Archived Nov 18, 2019

Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA).

HeraMED’s new age technology addresses age-old problems

Finfeed Archived Nov 14, 2019

Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength since listing on the ASX in December 2018.

ASX MedTech Transforming the US$50B Women’s Health Market

Next Investors Archived Nov 14, 2019

HeraMED (ASX:HMD) has a target market of 2 million pregnancies in 2020, 6 million in 2021 and 45 million in 2022.

Page 1 of 2 next >